Sugi Predict

Sugi Predict / Compounds / SCHEMBL8856

SCHEMBL8856

SCHEMBL8856

CCc1oc2ccc(F)cc2c(=O)c1-c1cccc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 10/20 0.53
▸ GABRB2 P47870 10/20 0.53
▸ GABRP O00591 9/20 0.53
▸ GABRD O14764 9/20 0.53
▸ GABRB1 P18505 9/20 0.53
▸ GABRG2 P18507 9/20 0.53
▸ GABRB3 P28472 9/20 0.53
▸ GABRA5 P31644 9/20 0.53
▸ GABRA3 P34903 9/20 0.53
▸ GABRA2 P47869 9/20 0.53
▸ GABRA4 P48169 9/20 0.53
▸ GABRE P78334 9/20 0.53
▸ GABRA6 Q16445 9/20 0.53
▸ GABRG1 Q8N1C3 9/20 0.53
▸ GABRG3 Q99928 9/20 0.53
▸ GABRQ Q9UN88 9/20 0.53
▸ TNKS O95271 1/20 0.45
▸ PIK3CD O00329 2/20 0.41
▸ PIK3CG P48736 2/20 0.41
▸ KMT2A Q03164 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9107 0.91 GABRP (0.56) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL9741 0.91 GABRP (0.52) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL8910 0.90 TNKS (0.52) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL9273 0.86 GABRP (0.53) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL8932 0.84 GABRP (0.51) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL15528285 0.84 GABRP (0.51) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL13717530 0.83 AR (0.42) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL20088129 0.82 AR (0.49) KMT2AMEN1KDM4ECA1CA2
SCHEMBL8632 0.82 GABRP (0.54) GABRA1GABRB2GABRPGABRDGABRB1
SCHEMBL8670 0.82 GABRP (0.57) GABRA1GABRB2GABRPGABRDGABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
EP-3756686-A1 COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR TG Therapeutics Inc. (US) 2020-12-30 — — EP disclosed
EP-3756686-A1 COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR TG Therapeutics Inc. (US) 2020-12-30 — — EP disclosed
US-20200323981-A1 Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor BLUE OWL CAPITAL CORPORATION 2020-10-15 — — US disclosed
US-10729768-B2 Combination of anti-CD20 antibody and PI3 kinase selective inhibitor TG THERAPEUTICS, INC. (US) 2020-08-04 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 — — US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 — — US disclosed
WO-2014071125-A1 COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR TG THERAPEUTICS, INC. (US) 2014-05-08 — — WO disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200323981-A1 Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor PIK3R4, PIK3R5, PIK3R1 GABRA1 733/4885GABRB2 1272/4885GABRP 1294/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRA1 3106/4885GABRB2 1664/4885GABRP 1342/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRA1 3106/4885GABRB2 1664/4885GABRP 1342/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRA1 3106/4885GABRB2 1664/4885GABRP 1342/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRA1 3106/4885GABRB2 1664/4885GABRP 1342/4885
US-10729768-B2 Combination of anti-CD20 antibody and PI3 kinase selective inhibitor PIK3R4, PIK3R5, PIK3CD GABRA1 846/4885GABRB2 1175/4885GABRP 907/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRA1 3106/4885GABRB2 1664/4885GABRP 1342/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A GABRA1 3473/4885GABRB2 3140/4885GABRP 2530/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRA1 3106/4885GABRB2 1664/4885GABRP 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.